Alicia Morgans: Hi, I’m thrilled to have here with me today, Tom Farrington, who is the Founder and President of the Prostate Health Education Network, PHEN, located in Boston, Massachusetts. Thank you so much for being here with me today. Tom Farrington: Alicia, it is great to be with you. Alicia Morgans: Thank you. I […]
Alicia Morgans: Hi. I’m delighted to have here with me today Dr. Carmel Pezaro who is a medical oncologist at the Sheffield Teaching Hospitals in the UK. Thank you so much for being here. Carmel Pezaro: It’s my absolute pleasure. It’s lovely to see you again. Alicia Morgans: And to see you too, especially since […]
Charles Ryan: Hello from ASCO 2019. I’m delighted to be joined today by Mike Morris, who’s a member at the Genitourinary Oncology Service and head of the prostate cancer program at Memorial Sloan Kettering Cancer Center, and Larry Schwartz, who’s a professor and chairman of the Department of Radiology at Columbia. You two have really […]
Monty Pal: Hi, I’m Monty pal. I’m a medical oncologist at the City of Hope Comprehensive Cancer Center and I’m here on behalf of UroToday to interview someone who I think is a superstar in the world of GU medical oncology. I follow her on the daily, on Twitter and it’s just wonderful to be […]
The aim of this study was to evaluate the efficacy and safety of chemoradiotherapy (RCT) combined with regional deep hyperthermia (RHT) of high-risk bladder cancer after transurethral resection of bladder tumor (TUR-BT). Between 1982 and 2016, 369 patients with pTa, pTis, pT1, and pT2 cN0-1 cM0 bladder cancer were treated with a multimodal treatment after […]
Bladder cancer is one of the most common malignancies of urinary tract. The current study aimed to investigate the role of insulin-like growth factor II messenger RNA binding protein 3 (IMP3) expression in the prognostic evaluation of non-muscle- invasive urothelial carcinoma of the bladder. Immunohistochemistry (IHC) was carried out to examine IMP3 protein expression in […]
Despite an overwhelming body of evidence showing the benefits of physical activity (PA) and exercise for cancer survivors, few survivors meet the exercise oncology guidelines. Moreover, initiating, let alone maintaining exercise programs with cancer survivors continues to have limited success. The aim of this trial is to evaluate the influence of peer support on moderate-to-vigorous […]
Radiation therapy (RT) is used to treat approximately 50% of all cancer patients. However, RT causes a wide range of adverse late effects that can affect a patient’s quality of life. There are currently no predictive assays in clinical use to identify patients at risk of normal tissue radiation toxicity. This study aimed to investigate […]
To determine practice patterns for the extent of lymphadenectomy at radical prostatectomy and associations with detection of pN1 prostate cancer, as well as the impact of lymphadenectomy extent on underdetection of pN1 disease and overall survival. Prostatectomy cases in the NCDB from 2004 to 2013 were included. Lymphadenectomy extent was defined by the number of […]
Patient decision aids (PDAs) can support the treatment decision making process and empower patients to take a proactive role in their treatment pathway while using a shared decision-making (SDM) approach making participatory medicine possible. The aim of this study was to develop a PDA for prostate cancer that is accurate and user-friendly. We followed a […]
